MPM Oncology Impact Management »

Viking Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Viking Therapeutics (VKTX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Viking Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Viking Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Viking Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $6.3M 119k 53.01
2024-03-31 $12M 150k 82.00
2023-09-30 $3.6M 325k 11.07

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Viking Therapeutics

Vanguard Group
BlackRock
BlackRock
State Street Corporation
Susquehanna International
Citadel Advisors
Jpmorgan Chase & Co
Geode Capital Management
Perceptive Advisors
Pictet Asset Management Holding SA
Perpetual
Alliancebernstein
Goldman Sachs Group
Braidwell
Jane Street

View all funds holding Viking Therapeutics